Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03330405 · ClinicalTrials.gov registry record · Phase 1
Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 223
- Enrollment target
NCT03330405 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 223 participants.
The verdict
NCT03330405, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 223 participants
- Enrollment target
Study Summary
Avelumab in combination with talazoparib will be investigated in patients with locally advanced (primary or recurrent) or metastatic solid tumors, including non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), hormone receptor positive (HR+) breast cancer, recurrent platinum sensitive ovarian cancer, urothelial cancer (UC), and castration resistant prostate cancer (CRPC).
Interventions
- DRUG Avelumab Phase 1b
- DRUG Talazoparib Phase 1b
- DRUG Avelumab Phase 2
- DRUG Talazoparib Phase 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 223 participants |
| Start Date | 2017-10-19 |
| Est. Completion | 2023-01-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03330405
The ClinicalTrials.gov registry entry for NCT03330405 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 223 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Avelumab Phase 1b is the first listed.
NCT03330405 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03330405 about?
NCT03330405 is a clinical study titled "Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors". Avelumab in combination with talazoparib will be investigated in patients with locally advanced (primary or recurrent) or metastatic solid tumors, including non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), hormone receptor positive (HR+) breast cancer, recurrent platinum sen...
What is the current status of trial NCT03330405?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 223 participants. The study started on 2017-10-19. Estimated completion is 2023-01-04.
What interventions are being tested in trial NCT03330405?
The interventions under investigation include: Avelumab Phase 1b (DRUG), Talazoparib Phase 1b (DRUG), Avelumab Phase 2 (DRUG), Talazoparib Phase 2 (DRUG).
Who is sponsoring clinical trial NCT03330405?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.